IMAGENE.ME, a Polish biotechnology company operating in the field of genomic research and genetic diagnostics, has secured funding amounting to 6 million PLN. The funds for development were provided by ABAN.VC and the NCBR Investment Fund (NIF). The company plans to use the capital to expand its current offerings in genetic diagnostics and personalized medicine, as well as to grow its presence in international markets.
IMAGENE.ME operates an attractive business model based on genetic and biomedical profiling of users. Its flagship product, IMAGENE.ME LIFE, is the world’s first platform that integrates genomic data with a tailored range of medical and wellbeing products and services, customized to individual needs.
Expansion with Innovation-Driven Partners
IMAGENE.ME is a company that bridges science, technology, and business. It develops its own products and services in the field of personal genomics while offering comprehensive support to partners in the healthcare sector, helping them adapt genomic solutions to their business needs. The backing from ABAN.VC and the NCBR Investment Fund will enhance the company’s potential to scale its operations and expand globally.
“Our mission is to provide access to valuable insights derived from comprehensive genome analysis to everyone who values proactive health management. IMAGENE.ME offers tools that translate DNA test results into tangible, health-promoting actions,” says Dr. hab. Mirosław Kwaśniewski, founder and Vice President of the IMAGENE.ME Board.
ABAN.VC, a fund with over 10 investments in its portfolio, recognized IMAGENE.ME as a company with exceptional potential, ready to scale its operations into international markets.
“The company has proven it can not only deliver innovative solutions but also effectively address global needs in health and longevity. It has demonstrated its ability to enter the challenging medical market with an innovative approach, build partnerships, and steadily strengthen its position in Poland. Given that IMAGENE.ME employs and develops a universal business model, we are supporting a company with the potential to become a leader in Europe,” emphasizes Piotr Kupczak, President of ABAN.VC.
The NCBR Investment Fund, which manages public funds with a mission to support Polish companies with significant scientific and innovative potential capable of succeeding internationally, praised IMAGENE.ME for its consistent efforts in translating cutting-edge scientific concepts and advanced technological solutions in genomics and large-scale biomedical data analysis into medical products and services.
“IMAGENE.ME is a remarkable example of how combining technology, science, and an innovative approach can create something truly unique in the Polish and European genomics and personalized medicine markets. The company delivers significant value in medical, scientific, and commercial terms. Our decision to support it stems from our belief that companies like this represent the future of personalized, proactive medicine focused on long-term health support. IMAGENE.ME has immense opportunities ahead, and as an investor, we will accompany it on its path to international expansion,” adds Marcin Syposz, Chairman of the Supervisory Board, temporarily performing the duties of the President of the NIF Board.
AI and Genomics Integration – The Future of Personalized Healthcare
IMAGENE.ME is actively developing tools based on artificial intelligence technology. The company possesses extensive knowledge bases that serve as the foundation for building an advanced health assistant to support both patients and medical professionals. The integration of AI will enable faster, more precise health predictions and the delivery of personalized recommendations in real time.
“Solutions that seemed like a vision of the future a few years ago are now being implemented with increasing boldness. In the field of genomics and genetic diagnostics, the scientific and medical communities are beginning to recognize the role of full genome sequencing and genetic variant analysis for polygenic traits, combined with clinical and behavioral data (PRS). We see studies where the integration of large language models (LLMs) into the patient-system-doctor relationship significantly improves understanding of results and boosts patient engagement in treatment and preventive measures. These are the directions we are pursuing and where we place great hope in our international expansion process,” stresses Dr. Kwaśniewski.
IMAGENE.ME is steadily advancing its operations by combining the latest achievements in genomics with the possibilities of artificial intelligence. The company observes a significant market shift toward health prevention and the use of integrated patient data. Strategic partnerships, such as its collaboration with the DIAGNOSTYKA group on the LONGEVITY+ project, are particularly vital to its growth.
“Artificial intelligence will bring us even closer to realizing our vision, where everyone can use genetic analysis results in everyday life, and medical professionals gain access to tools that enhance their ability to support patients effectively. This is a future within our reach,” adds Jacek Bajerski, Board Member for Operations and Technology at IMAGENE.ME.
Source: https://managerplus.pl/imagene-me-pozyskuje-6-mln-zl-na-rozwoj-diagnostyki-genetycznej-i-ekspansje-zagraniczna-94541
